QS

Quantum-Si Incorporated Class A Common Stock Earnings Recaps

QSI Health Care 2 recaps
Next earnings: November 4, 2026 (estimated) · full calendar
Q2 2026 Aug 15, 2026

Quantum-Si’s shares dropped 11.7% following the earnings release as the company delayed the Proteus instrument launch by about six months, citing a need for an additional integrated design cycle to reduce execution risk. Investors reacted negatively to the increased timeline, cautious outlook, and margin pressure from associated cost-cutting measures.

Key takeaways
  • Proteus launch timeline postponed from end of 2026 to Q2 2027, adding an extra integrated instrument design cycle.
  • Management initiated operating expense reductions to cut cash burn and align costs with the delayed product timeline, impacting near-term margin outlook.
  • Proteus technology remains fundamentally sound based on sequencing data, but management chose to prioritize derisking the product to ensure readiness and customer experience at launch.
  • Shift in Library Preparation strategy from a single generic kit to multiple application-specific kits aims to reduce technical risk and accelerate capability delivery at scale.
  • While progress continues in recognizing amino acids (17 detected so far), the delay allows more time to advance to detecting 19–20 amino acids before launch.
Full recap
Q3 2025 Nov 6, 2025

Quantum-Si's third-quarter results reflect ongoing challenges in capital sales, with revenues of $552,000; however, strategic initiatives have led to the acquisition of 12 new customers and significant progress in product innovation.

Key takeaways
  • Revenue of $552,000, impacted by persistent capital sales headwinds.
  • Successfully onboarded 12 new customers, over half from academic labs, following the launch of flexible instrument acquisition options.
  • Completed sequencing runs on multiple prototype Proteus systems, marking a key milestone in product development.
  • Launched a version 4 sequencing kit in September, enhancing amino acid detection capabilities for customers.
  • Active pipeline of publications with five manuscripts submitted, supporting increased scientific validation and market awareness.
Full recap

Go deeper on QSI and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.